1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Small Business Innovation Research (SBIR) Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This grant encourages small businesses to develop innovative technologies in biomedical research, including digital health tools, medical devices, and other health-related innovations.
It provides non-dilutive funding for early-stage R&D.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-based, for-profit small business concerns with no more than 500 employees, primarily owned by U.S. citizens or permanent residents. Confirm the full requirements in the official notice before applying.
The current listing shows phase I: up to $323,090; Phase II: up to $2,153,927 (amounts vary by institute). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NIH Small Business Innovation Research (SBIR) Grant (Parent SBIR [R43/R44] Clinical Trial Optional) are due April 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH Small Business Innovation Research (SBIR) Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Innovation Research (SBIR) PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-23-230) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program supports small businesses in developing innovative technologies in biomedical research, including clinical decision support tools and other health IT solutions. It funds feasibility studies and research and development needed for commercialization.
NIH Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This omnibus solicitation supports small business innovation research across a broad spectrum of topic areas, including those relevant to brain-computer interfaces. It is a parent announcement for SBIR grants where a clinical trial may be optional.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read articleBloomberg Philanthropies committed $150 million on October 20, 2026 to its Overdose Prevention Initiative, adding Washington state, continuing in Kentucky, New Jersey, New Mexico, North Carolina and Wisconsin, and exiting the two original 2018 states. The money flows through state partnerships, not an open call. Here is how organizations in those states can actually engage.
Read article